<DOC>
	<DOCNO>NCT00158522</DOCNO>
	<brief_summary>Acute hepatitis C liver disease relate virus : hepatitis C virus ( HCV ) . The type Hepatitis C Virus present Egypt ( genotype 4 ) , reputation respond poorly treatment chronic hepatitis stage . Without treatment , 85 % patient acute hepatitis C become chronically HCV infect mean virus stay present body . Pegylated Interferon new form Interferon stay body long time allow patient take less injection per week . It also prove effective standard Interferon treatment chronic hepatitis C .</brief_summary>
	<brief_title>Efficacy Pegylated Interferon Alone Egyptian Patients With Acute Hepatitis C ( ANRS 1213 )</brief_title>
	<detailed_description>Egypt country high HCV prevalence worldwide , number infect Egyptians estimate around 8 million . HCV incidence high well , typical hepatology department Cairo diagnose 5 10 acute hepatitis C per month . The HCV genotype circulate Egypt genotype 4 . This genotype reputation respond poorly treatment chronic hepatitis stage . It would therefore interesting ass treatment efficacy acute stage . This study evaluate efficacy pegylated interferon ( peg-IFNα-2a ) alone Egyptian patient acute hepatitis C. The study primary objective evaluate efficacy tolerance pegylated interferon ( peg-IFNα-2a ) alone Egyptian patient acute hepatitis C. Methods : One arm clinical trial . Follow-up duration : 36 48 week depend response treatment . Main inclusion criterion : ALT &gt; 3*N ; HCV RNA positive PCR negative HCV serology first presentation positive HCV serology clear unique exposure within 2 month prior acute hepatitis episode ; prior treatment IFNα , peg-IFNα ribavirin ; sign informed consent . Main exclusion criterion : Liver disease hepatitis C. Treatment strategy : Peg-IFNα-2a 180microg/week ( subcutaneous injection ) 12 week . Patients positive HCV RNA qualitative PCR end 12 week treatment period offer continue regimen 24 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Acute hepatitis C : ( 1 ) ALT 3x normal value ; IgM antiHAV , IgM antiHBc negative antibody ; negative HCV antibody ( 3rd generation ELISA ) positive HCV PCR first presentation , , ( 2 ) ALT 4x normal value ; IgM antiHAV , IgM antiHBc , CMV , EBV toxoplasmoses negative antibody negative HEV PCR ; Positive HCV antibody ( 3rd generation ELISA ) positive HCV PCR first presentation ; clear history exposure within 2 month prior time diagnosis ; exposure hepatotoxic drug pesticide within 2 week prior time diagnosis Patients without chronic liver disease HBsAg negative Hemoglobin equal 11g/dl Leucocytes equal 3000/mm3 Polynuclear neutrophil equal 1500/mm3 Platelets equal 100 000/mm3 Blood creatinin less equal 150 micromol/l Blood uric acid within normal limit investigate center Normal TSH Antinuclear antibodies &lt; 1/160 Fasting blood sugar 70115 mg/dl ; glucose intolerance diabetes , HbA1C le equal 8,5 % Normal ophthalmologic examination patient Effective contraception treatment period . No breastfeed study period Signed informed consent Coinfection hepatitis B ( positive HBs antigen ) Hemochromatosis Alpha1 antitrypsin deficiency Wilson disease Alcoholismrelated liver disease Gilbert disease Liver cirrhosis Hepatocellular carcinoma . Alcohol intake 50g/day male 40 g/day female Intravenous drug use Psychiatric disease : history severe nervous breakdown severe psychiatric disease major psychosis , suicidal idea , suicide attempts… Epilepsy Autoimmune disease Heart disease six month precede enrolment patient significant change EKG Uncontrolled diabetes Chronic respiratory insufficiency hypoxemia 10 kPa Medical surgical condition nonstabilized , life expectancy low two year Pregnancy breastfeed Unavailability regular followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Acute hepatitis C</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Egypt</keyword>
</DOC>